GlaxoSmithKline (NYSE: GSK) announced on Wednesday that it has hired former Goldman Sachs Group Inc. (NYSE: GS) investment banker Simon Dingemans as its new chief financial officer. Dingemans will succeed the company’s current chief financial officer, Julian Heslop, 59, who will retire next March.
Mr. Dingemans has more than 25 years of experience working in investment banking and most recently led Goldman Sachs Group Inc. (NYSE: GS)’s European M&A business, the company said in a statement.
GlasoSmithKline CEO Andrew Witty said that the appointment reflected the need for the company to continue to operate with creativity and fiscal discipline. “Simon will bring valuable experience and capability to support us in our strategy to grow and diversify GSK’s business through organic means and bolt-on acquisitions,” he said.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatalogicals and vaccines. The Company’s segments include Pharmaceuticals and Consumer Healthcare. On July 22, 2009, it acquired Stiefel Laboratories, Inc. On October 30, 2009, it acquired Pfizer Inc.’s HIV business and combined it with its own HIV business to form ViiV Healthcare Limited. On November 10, 2009, it acquired the Algerian pharmaceutical, manufacturing and distribution group, Laboratoire Pharmaceutique Algerien. On December 18, 2009, it acquired NovaMin Technology Inc.
Shares of GSK traded up 1.41% hitting $39.48 during mid-day trading on Monday.
